206 related articles for article (PubMed ID: 27169737)
21. Ca2+ signaling in human induced pluripotent stem cell-derived cardiomyocytes (iPS-CM) from normal and catecholaminergic polymorphic ventricular tachycardia (CPVT)-afflicted subjects.
Zhang XH; Haviland S; Wei H; Sarić T; Fatima A; Hescheler J; Cleemann L; Morad M
Cell Calcium; 2013 Aug; 54(2):57-70. PubMed ID: 23684427
[TBL] [Abstract][Full Text] [Related]
22. Short communication: flecainide exerts an antiarrhythmic effect in a mouse model of catecholaminergic polymorphic ventricular tachycardia by increasing the threshold for triggered activity.
Liu N; Denegri M; Ruan Y; Avelino-Cruz JE; Perissi A; Negri S; Napolitano C; Coetzee WA; Boyden PA; Priori SG
Circ Res; 2011 Jul; 109(3):291-5. PubMed ID: 21680895
[TBL] [Abstract][Full Text] [Related]
23. Slowed depolarization and irregular repolarization in catecholaminergic polymorphic ventricular tachycardia: a study from cellular Ca2+ transients and action potentials to clinical monophasic action potentials and electrocardiography.
Paavola J; Väänänen H; Larsson K; Penttinen K; Toivonen L; Kontula K; Laine M; Aalto-Setälä K; Swan H; Viitasalo M
Europace; 2016 Oct; 18(10):1599-1607. PubMed ID: 26705554
[TBL] [Abstract][Full Text] [Related]
24. The mechanism of flecainide action in CPVT does not involve a direct effect on RyR2.
Bannister ML; Thomas NL; Sikkel MB; Mukherjee S; Maxwell C; MacLeod KT; George CH; Williams AJ
Circ Res; 2015 Apr; 116(8):1324-35. PubMed ID: 25648700
[TBL] [Abstract][Full Text] [Related]
25. Suppression of ryanodine receptor function prolongs Ca2+ release refractoriness and promotes cardiac alternans in intact hearts.
Zhong X; Sun B; Vallmitjana A; Mi T; Guo W; Ni M; Wang R; Guo A; Duff HJ; Gillis AM; Song LS; Hove-Madsen L; Benitez R; Chen SR
Biochem J; 2016 Nov; 473(21):3951-3964. PubMed ID: 27582498
[TBL] [Abstract][Full Text] [Related]
26. Distinct mechanisms mediate pacemaker dysfunction associated with catecholaminergic polymorphic ventricular tachycardia mutations: Insights from computational modeling.
Arbel-Ganon L; Behar JA; Gómez AM; Yaniv Y
J Mol Cell Cardiol; 2020 Jun; 143():85-95. PubMed ID: 32339564
[TBL] [Abstract][Full Text] [Related]
27. Mutant ryanodine receptors in catecholaminergic polymorphic ventricular tachycardia generate delayed afterdepolarizations due to increased propensity to Ca2+ waves.
Paavola J; Viitasalo M; Laitinen-Forsblom PJ; Pasternack M; Swan H; Tikkanen I; Toivonen L; Kontula K; Laine M
Eur Heart J; 2007 May; 28(9):1135-42. PubMed ID: 17347175
[TBL] [Abstract][Full Text] [Related]
28. R4496C RyR2 mutation impairs atrial and ventricular contractility.
Ferrantini C; Coppini R; Scellini B; Ferrara C; Pioner JM; Mazzoni L; Priori S; Cerbai E; Tesi C; Poggesi C
J Gen Physiol; 2016 Jan; 147(1):39-52. PubMed ID: 26666913
[TBL] [Abstract][Full Text] [Related]
29. Enhanced binding of calmodulin to RyR2 corrects arrhythmogenic channel disorder in CPVT-associated myocytes.
Fukuda M; Yamamoto T; Nishimura S; Kato T; Murakami W; Hino A; Ono M; Tateishi H; Oda T; Okuda S; Kobayashi S; Koseki N; Kyushiki H; Yano M
Biochem Biophys Res Commun; 2014 May; 448(1):1-7. PubMed ID: 24755079
[TBL] [Abstract][Full Text] [Related]
30. Secretoneurin Is an Endogenous Calcium/Calmodulin-Dependent Protein Kinase II Inhibitor That Attenuates Ca
Ottesen AH; Carlson CR; Eken OS; Sadredini M; Myhre PL; Shen X; Dalhus B; Laver DR; Lunde PK; Kurola J; Lunde M; Hoff JE; Godang K; Sjaastad I; Pettilä V; Stridsberg M; Lehnart SE; Edwards AG; Lunde IG; Omland T; Stokke MK; Christensen G; Røsjø H; Louch WE
Circ Arrhythm Electrophysiol; 2019 Apr; 12(4):e007045. PubMed ID: 30943765
[TBL] [Abstract][Full Text] [Related]
31. Flecainide inhibits arrhythmogenic Ca2+ waves by open state block of ryanodine receptor Ca2+ release channels and reduction of Ca2+ spark mass.
Hilliard FA; Steele DS; Laver D; Yang Z; Le Marchand SJ; Chopra N; Piston DW; Huke S; Knollmann BC
J Mol Cell Cardiol; 2010 Feb; 48(2):293-301. PubMed ID: 19835880
[TBL] [Abstract][Full Text] [Related]
32. Pathogenic mechanism of a catecholaminergic polymorphic ventricular tachycardia causing-mutation in cardiac calcium release channel RyR2.
Xiong J; Liu X; Gong Y; Zhang P; Qiang S; Zhao Q; Guo R; Qian Y; Wang L; Zhu L; Wang R; Hao Z; Wen H; Zhang J; Tang K; Zang WF; Yuchi Z; Chen H; Chen SRW; Zheng W; Wang SQ; Xu YW; Liu Z
J Mol Cell Cardiol; 2018 Apr; 117():26-35. PubMed ID: 29477366
[TBL] [Abstract][Full Text] [Related]
33. Accelerated sinus rhythm prevents catecholaminergic polymorphic ventricular tachycardia in mice and in patients.
Faggioni M; Hwang HS; van der Werf C; Nederend I; Kannankeril PJ; Wilde AA; Knollmann BC
Circ Res; 2013 Feb; 112(4):689-97. PubMed ID: 23295832
[TBL] [Abstract][Full Text] [Related]
34. Catecholaminergic polymorphic ventricular tachycardia is caused by mutation-linked defective conformational regulation of the ryanodine receptor.
Uchinoumi H; Yano M; Suetomi T; Ono M; Xu X; Tateishi H; Oda T; Okuda S; Doi M; Kobayashi S; Yamamoto T; Ikeda Y; Ohkusa T; Ikemoto N; Matsuzaki M
Circ Res; 2010 Apr; 106(8):1413-24. PubMed ID: 20224043
[TBL] [Abstract][Full Text] [Related]
35. Subclinical abnormalities in sarcoplasmic reticulum Ca(2+) release promote eccentric myocardial remodeling and pump failure death in response to pressure overload.
Sedej S; Schmidt A; Denegri M; Walther S; Matovina M; Arnstein G; Gutschi EM; Windhager I; Ljubojević S; Negri S; Heinzel FR; Bisping E; Vos MA; Napolitano C; Priori SG; Kockskämper J; Pieske B
J Am Coll Cardiol; 2014 Apr; 63(15):1569-79. PubMed ID: 24315909
[TBL] [Abstract][Full Text] [Related]
36. Nebivolol suppresses cardiac ryanodine receptor-mediated spontaneous Ca2+ release and catecholaminergic polymorphic ventricular tachycardia.
Tan Z; Xiao Z; Wei J; Zhang J; Zhou Q; Smith CD; Nani A; Wu G; Song LS; Back TG; Fill M; Chen SR
Biochem J; 2016 Nov; 473(22):4159-4172. PubMed ID: 27623776
[TBL] [Abstract][Full Text] [Related]
37. Arrhythmogenic mechanisms in a mouse model of catecholaminergic polymorphic ventricular tachycardia.
Cerrone M; Noujaim SF; Tolkacheva EG; Talkachou A; O'Connell R; Berenfeld O; Anumonwo J; Pandit SV; Vikstrom K; Napolitano C; Priori SG; Jalife J
Circ Res; 2007 Nov; 101(10):1039-48. PubMed ID: 17872467
[TBL] [Abstract][Full Text] [Related]
38. Neuronal Na+ channel blockade suppresses arrhythmogenic diastolic Ca2+ release.
Radwański PB; Brunello L; Veeraraghavan R; Ho HT; Lou Q; Makara MA; Belevych AE; Anghelescu M; Priori SG; Volpe P; Hund TJ; Janssen PM; Mohler PJ; Bridge JH; Poelzing S; Györke S
Cardiovasc Res; 2015 Apr; 106(1):143-52. PubMed ID: 25538156
[TBL] [Abstract][Full Text] [Related]
39. Z16b, a natural compound from Ganoderma cochlear is a novel RyR2 stabilizer preventing catecholaminergic polymorphic ventricular tachycardia.
Wan JF; Wang G; Qin FY; Huang DL; Wang Y; Su AL; Zhang HP; Liu Y; Zeng SY; Wei CL; Cheng YX; Liu J
Acta Pharmacol Sin; 2022 Sep; 43(9):2340-2350. PubMed ID: 35190699
[TBL] [Abstract][Full Text] [Related]
40. Heterogeneity of ryanodine receptor dysfunction in a mouse model of catecholaminergic polymorphic ventricular tachycardia.
Loaiza R; Benkusky NA; Powers PP; Hacker T; Noujaim S; Ackerman MJ; Jalife J; Valdivia HH
Circ Res; 2013 Jan; 112(2):298-308. PubMed ID: 23152493
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
